-
公开(公告)号：US10251868B2
公开(公告)日：2019-04-09
申请号：US15876619
申请日：2018-01-22
Applicant: NOVARTIS AG
Inventor： Jun Cao , Bernhard Erb , Robin Alec Fairhurst , Arnaud Grandeury , Shinji Hatakeyama , Magdalena Koziczak-Holbro , Xinzhong Lai , Philipp Lustenberger , Bernd Ulrich Riebesehl , Nicola Tufilli , Thomas Ullrich , Xiang Wu , Jianguang Zhou
IPC: A61K31/428 , A61K31/167 , C07D277/68 , C07C53/10 , A61K45/06
Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
-
公开(公告)号：US10919887B2
公开(公告)日：2021-02-16
申请号：US15762724
申请日：2016-09-20
Applicant: Novartis AG
Inventor： Eric Aubin , Anthony Casarez , Andreas Fisch , Zaixing Li , Mika Lindvall , Heinz Ernst Moser , Michael Mutz , Folkert Reck , Bernd Ulrich Riebesehl , Marc Schoenhentz , Vijay Sethuraman , Robert Lowell Simmons
IPC: C07D417/14 , A61P31/04
Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.
-
公开(公告)号：US20210177824A1
公开(公告)日：2021-06-17
申请号：US16761779
申请日：2018-11-08
Applicant: NOVARTIS AG
Inventor： Carlo Castagnoli , Andreas Fisch , Mathilde Lorscheider , Manjali Laxman Neharkar , Bernd Ulrich Riebesehl
Abstract: The present invention relates to a pharmaceutical composition comprising an aqueous suspension of: (i) crystalline N-(3,4-dichlorophenyl)-3-(pyridin-4-yl)-7-oxabicyclo[2.2.1]heptane-2-carboxamide or a pharmaceutically acceptable salt thereof; and (ii) a surfactant comprising a water-soluble co-polymer characterized by >5% solubility in water at 25° C. The compositions provide extended release of N-(3,4-dichlorophenyl)-3-(pyridin-4-yl)-7-oxabicyclo[2.2.1] heptane-2-carboxamide, and are suitable for intra-articular injection to a joint of a patient suffering from arthritis, joint injury or cartilage injury.
-
公开(公告)号：US09913828B2
公开(公告)日：2018-03-13
申请号：US15178579
申请日：2016-06-10
Applicant: Novartis AG
Inventor： Jun Cao , Bernhard Erb , Robin Alec Fairhurst , Arnaud Grandeury , Shinji Hatakeyama , Magdalena Koziczak-Holbro , Xinzhong Lai , Philipp Lustenberger , Bernd Ulrich Riebesehl , Nicola Tufilli , Thomas Ullrich , Xiang Wu , Jianguang Zhou
IPC: A61K31/428 , C07D277/68 , A61K45/06 , A61K31/167 , C07C53/10
CPC classification number: A61K31/428 , A61K31/167 , A61K45/06 , C07B2200/07 , C07C53/10 , C07D277/68 , Y02P20/55
Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
-
-
-
Search Results
4
records
(took 0.011 seconds)
